Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts
for the highest mortality rate among these cancers. A stepwise approach to assessment …

Ovarian cancer (OC) is one of the most common gynecologic tumors worldwide and one
with the highest mortality. Cisplatin (DDP) is the first platinum-based complex approved by …

Epithelial ovarian cancer (EOC) represents a heterogeneous spectrum of disease entities at
a clinical, pathological and molecular level. Ovarian cancer is the second most lethal …

PURPOSE To evaluate the impact of two different intraperitoneal (IP) chemotherapy
regimens on progression-free survival (PFS) among women with newly diagnosed …

Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of
chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the …

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …

The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …

Background Carboplatin plus paclitaxel administered every 3 weeks is standard first-line
chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule …

Highlights•Platinum-based chemotherapy remains the most active treatment for ovarian
cancer.•Platinum should not be withheld after response to last platinum and a treatment-free …

Background Anti-angiogenic therapy combined with chemotherapy could improve the
outcomes of patients with platinum-resistant ovarian cancer. Apatinib is an oral tyrosine …